NEO:HALO

Halozyme Therapeutics Competitors

C$43.41

+1.64 (+3.93 %)

(As of 05/14/2021 01:21 PM ET)

Add

Compare

Today's Range

C$41.69

▼

C$43.43

50-Day Range N/A

52-Week Range

C$22.11

▼

C$56.40

Volume9,947 shs

Average Volume1.32 million shs

Market CapitalizationC$6.18 billion

P/E Ratio47.70

Dividend YieldN/A

BetaN/A

Halozyme Therapeutics (NEO:HALO) Vs. CHV, PREV, COM, MYM, CURE, and LTY

Should you be buying HALO stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Halozyme Therapeutics, including (CHV) (CHV), (PREV) (PREV), 138267 (COM.TO) (COM), 17031 (MYM), Direxion Daily Healthcare Bull 3X Shares (CURE), and Liberty Biopharma (LTY).

Halozyme Therapeutics vs. (CHV) Stock

Halozyme Therapeutics (NEO:HALO) and (CHV) (CNSX:CHV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Halozyme Therapeutics and (CHV), as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	0	0	0	1	4.00
(CHV)	0	0	0	0	N/A

Halozyme Therapeutics currently has a consensus target price of C$0.24, indicating a potential downside of 99.45%.

Profitability

This table compares Halozyme Therapeutics and (CHV)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	N/A	N/A	N/A
(CHV)	N/A	N/A	N/A

Valuation & Earnings

This table compares Halozyme Therapeutics and (CHV)'s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	C$267.59 million	23.10	$129.57 million	C$0.91	47.70
(CHV)	N/A	N/A	N/A	N/A	N/A

Halozyme Therapeutics has higher revenue and earnings than (CHV).

Summary

Halozyme Therapeutics beats (CHV) on 2 of the 2 factors compared between the two stocks.

Halozyme Therapeutics vs. (PREV) Stock

Halozyme Therapeutics (NEO:HALO) and (PREV) (CNSX:PREV) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Halozyme Therapeutics and (PREV), as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	0	0	0	1	4.00
(PREV)	0	0	0	0	N/A

Halozyme Therapeutics currently has a consensus target price of C$0.24, indicating a potential downside of 99.45%.

Profitability

This table compares Halozyme Therapeutics and (PREV)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	N/A	N/A	N/A
(PREV)	N/A	N/A	N/A

Valuation & Earnings

This table compares Halozyme Therapeutics and (PREV)'s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	C$267.59 million	23.10	$129.57 million	C$0.91	47.70
(PREV)	N/A	N/A	N/A	N/A	N/A

Halozyme Therapeutics has higher revenue and earnings than (PREV).

Summary

Halozyme Therapeutics beats (PREV) on 2 of the 2 factors compared between the two stocks.

Halozyme Therapeutics vs. 138267 (COM.TO) Stock

Halozyme Therapeutics (NEO:HALO) and 138267 (COM.TO) (TSE:COM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Halozyme Therapeutics and 138267 (COM.TO), as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	0	0	0	1	4.00
138267 (COM.TO)	0	0	0	0	N/A

Halozyme Therapeutics currently has a consensus target price of C$0.24, indicating a potential downside of 99.45%.

Profitability

This table compares Halozyme Therapeutics and 138267 (COM.TO)'s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	N/A	N/A	N/A
138267 (COM.TO)	N/A	N/A	N/A

Valuation & Earnings

This table compares Halozyme Therapeutics and 138267 (COM.TO)'s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	C$267.59 million	23.10	C$129.57 million	C$0.91	47.70
138267 (COM.TO)	N/A	N/A	N/A	N/A	N/A

Halozyme Therapeutics has higher revenue and earnings than 138267 (COM.TO).

Summary

Halozyme Therapeutics beats 138267 (COM.TO) on 2 of the 2 factors compared between the two stocks.

Halozyme Therapeutics vs. 17031 Stock

Halozyme Therapeutics (NEO:HALO) and 17031 (CNSX:MYM) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Halozyme Therapeutics and 17031, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	0	0	0	1	4.00
17031	0	0	0	0	N/A

Halozyme Therapeutics currently has a consensus target price of C$0.24, indicating a potential downside of 99.45%.

Profitability

This table compares Halozyme Therapeutics and 17031's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	N/A	N/A	N/A
17031	N/A	N/A	N/A

Valuation & Earnings

This table compares Halozyme Therapeutics and 17031's revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	C$267.59 million	23.10	C$129.57 million	C$0.91	47.70
17031	N/A	N/A	N/A	N/A	N/A

Halozyme Therapeutics has higher revenue and earnings than 17031.

Summary

Halozyme Therapeutics beats 17031 on 2 of the 2 factors compared between the two stocks.

Halozyme Therapeutics vs. Direxion Daily Healthcare Bull 3X Shares Stock

Halozyme Therapeutics (NEO:HALO) and Direxion Daily Healthcare Bull 3X Shares (CNSX:CURE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Profitability

This table compares Halozyme Therapeutics and Direxion Daily Healthcare Bull 3X Shares' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	N/A	N/A	N/A
Direxion Daily Healthcare Bull 3X Shares	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and target prices for Halozyme Therapeutics and Direxion Daily Healthcare Bull 3X Shares, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	0	0	0	1	4.00
Direxion Daily Healthcare Bull 3X Shares	0	0	0	0	N/A

Halozyme Therapeutics currently has a consensus target price of C$0.24, indicating a potential downside of 99.45%.

Valuation & Earnings

This table compares Halozyme Therapeutics and Direxion Daily Healthcare Bull 3X Shares' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	C$267.59 million	23.10	$129.57 million	C$0.91	47.70
Direxion Daily Healthcare Bull 3X Shares	N/A	N/A	N/A	N/A	N/A

Halozyme Therapeutics has higher revenue and earnings than Direxion Daily Healthcare Bull 3X Shares.

Summary

Halozyme Therapeutics beats Direxion Daily Healthcare Bull 3X Shares on 2 of the 2 factors compared between the two stocks.

Halozyme Therapeutics vs. Liberty Biopharma Stock

Liberty Biopharma (CVE:LTY) and Halozyme Therapeutics (NEO:HALO) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Profitability

This table compares Liberty Biopharma and Halozyme Therapeutics' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Liberty Biopharma	N/A	N/A	N/A
Halozyme Therapeutics	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Liberty Biopharma and Halozyme Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liberty Biopharma	0	0	0	0	N/A
Halozyme Therapeutics	0	0	0	1	4.00

Halozyme Therapeutics has a consensus target price of C$0.24, indicating a potential downside of 99.45%. Given Halozyme Therapeutics' higher possible upside, analysts clearly believe Halozyme Therapeutics is more favorable than Liberty Biopharma.

Earnings & Valuation

This table compares Liberty Biopharma and Halozyme Therapeutics' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liberty Biopharma	N/A	N/A	N/A	C($0.16)	-12.66
Halozyme Therapeutics	C$267.59 million	23.10	C$129.57 million	C$0.91	47.70

Halozyme Therapeutics has higher revenue and earnings than Liberty Biopharma. Liberty Biopharma is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Halozyme Therapeutics beats Liberty Biopharma on 5 of the 5 factors compared between the two stocks.